Patient-specific compartmental models for [177Lu]LuPSMA-617 therapy

被引:0
|
作者
Li, W. [1 ]
Kupitz, D. [2 ,3 ]
Spielmann, V. [1 ]
Kamp, A. [1 ]
Katzdobler, L. [1 ]
Giussani, A. [1 ]
Kreissl, M. [2 ,3 ,4 ]
Grosser, O. [2 ,3 ,4 ]
机构
[1] Bundesamt Strahlenschutz, Oberschleissheim, Germany
[2] Otto von Guericke Univ, Univ Hosp Magdeburg, Dept Radiol & Nucl Med, Magdeburg, Germany
[3] Otto von Guericke Univ, Fac Med, Magdeburg, Germany
[4] Otto von Guericke Univ, Res Campus STIMULATE, Magdeburg, Germany
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
EP-0920
引用
收藏
页码:S799 / S800
页数:2
相关论文
共 50 条
  • [41] Lu-177-PSMA-617 Therapy in a Patient with Chronic Renal Failure
    Mercolli, L.
    Mingels, C.
    Zeimpekis, K.
    Xue, S.
    Alberts, I.
    Uehlinger, D.
    Rominger, A.
    Afshar-Oromieh, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S13 - S13
  • [42] Requirements on specific activity (SA) of 177Lu to radiolabel DOTATATE for PRRT: studies on labeling 0.2 mg DOTATATE with 7.4 GBq 177Lu at several SA of 177Lu
    Breeman, W. A. P.
    de Blois, E.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [43] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [44] STABILITY STUDIES OF [177LU]-DOTATATE ([177LU]-LUTATE) FOR PEPTIDE RECEPTOR RADIONUCLIDE THERAPY USING CARRIER ADDED AND NON-CARRIER ADDED [177LU]-LUTETIUM
    Yasmin, L.
    Aslani, A.
    Bailey, D.
    INTERNAL MEDICINE JOURNAL, 2019, 49 : 41 - 41
  • [45] Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
    Uijen, Maike J. M.
    Prive, Bastiaan M.
    van Herpen, Carla M. L.
    Westdorp, Harm
    van Gemert, Willemijn A.
    de Bakker, Maarten
    Gotthardt, Martin
    Konijnenberg, Mark W.
    Peters, Steffie M. B.
    Nagarajah, James
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (04) : 270 - 275
  • [46] Patient-Specific Dosimetry of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy with High Activities
    Beykan, S.
    Eberlein, U.
    Werner, R. A.
    Lapa, C.
    Buck, A. K.
    Kudlich, T.
    Lassmann, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S33 - S33
  • [47] Modelling of a Patient-Specific 177Lu-Dotatate Therapy Renal Dosimetry Process for Investigation of Uncertainties
    Gustafsson, J.
    Brolin, G.
    Cox, M.
    Ljungberg, M.
    Johansson, L.
    Gleisner, K. Sjogreen
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S158 - S158
  • [48] Patient outcomes after therapy with 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.
    Vaz, Nuno
    Ritzer, Jolivette
    Wolanski, Andrew
    Bhimaniya, Sudhir
    Choudhury, Atish Dipankar
    Hyun, Hyewon
    Kelly, Emma
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    Pomerantz, Mark
    Robertson, Matthew
    Sakellis, Christopher
    Shah, Hina
    Sunkara, Rajitha
    Taplin, Mary-Ellen
    Wei, Xiao X.
    Whelpley, Bridget
    Ravi, Praful
    Jacene, Heather
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 87 - 87
  • [49] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
    Clements, Sarah
    Tempesta, Daniel
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
  • [50] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Anna Yordanova
    Paula Linden
    Stefan Hauser
    Michael Meisenheimer
    Stefan Kürpig
    Georg Feldmann
    Florian C. Gaertner
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1073 - 1080